Literature DB >> 9578174

Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland.

C E Goldsmith, J E Moore, P G Murphy, J E Ambler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9578174     DOI： 10.1093/jac/41.3.420

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  14 in total

1.  Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.

Authors:  V J Heaton; C E Goldsmith; J E Ambler; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

2.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

3.  Longitudinal assessment of antipneumococcal susceptibility in the United States.

Authors:  Mark E Jones; James A Karlowsky; Renée Blosser-Middleton; Ian A Critchley; Elena Karginova; Clyde Thornsberry; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

4.  High genetic diversity of ciprofloxacin-nonsusceptible isolates of Streptococcus pneumoniae in Poland.

Authors:  Ewa Sadowy; Radosław Izdebski; Anna Skoczyńska; Marek Gniadkowski; Waleria Hryniewicz
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

5.  In vitro activity of DX-619, a novel des-fluoro(6) quinolone, against a panel of Streptococcus pneumoniae mutants with characterized resistance mechanisms.

Authors:  Paul A Wickman; Ellen Smith Moland; Jennifer A Black; Kenneth S Thomson
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

6.  Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.

Authors:  M E Jones; A M Staples; I Critchley; C Thornsberry; P Heinze; H D Engler; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

7.  Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States.

Authors:  D F Sahm; D E Peterson; I A Critchley; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

8.  Risk factors associated with colonization by pneumococci with reduced susceptibility to fluoroquinolones in adult outpatients.

Authors:  M Raquel Marín Jiménez; Juan Luis Muñoz Bellido; José Angel García Rodríguez
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

9.  In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.

Authors:  Kazuko Yamamoto; Katsunori Yanagihara; Kazuyuki Sugahara; Yoshifumi Imamura; Masafumi Seki; Koichi Izumikawa; Hiroshi Kakeya; Yoshihiro Yamamoto; Yoichi Hirakata; Shimeru Kamihira; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

10.  Comparison of Clarithromycin and Amoxicillin/Clavulanic Acid for Community-Acquired Pneumonia in an Era of Drug-Resistant Streptococcus pneumoniae.

Authors:  Pablo Bonvehi; Katherine Weber; Todd Busman; Dee Shortridge; Gerard Notario
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.